Telehealth Narcolepsy Prescribing: What Prescribers Can Do in New York

You’re a psychiatrist scrolling through patient inquiries at 9 PM. One catches your eye: a 28-year-old in rural Pennsylvania who’s been struggling with excessive daytime sleepiness for years, recently diagnosed with narcolepsy by a sleep specialist, and now needs ongoing medication management. The nearest psychiatrist who treats narcolepsy is 90 miles away. Can you help them via telehealth? More importantly — can you legally prescribe their stimulant medication without ever seeing them in person?

If you’re wondering about the regulatory maze of telehealth narcolepsy prescribing, you’re not alone. The rules have shifted dramatically since 2020, and they vary wildly by state. Here’s what you actually need to know to practice confidently and compliantly.

The Short Answer: Yes, Psychiatrists Can Prescribe Narcolepsy Meds via Telehealth (With Caveats)

As of early 2026, psychiatrists have full authority to diagnose and treat narcolepsy via telehealth in most states, including prescribing Schedule II stimulants like Adderall, Ritalin, or newer agents like Sunosi and Wakix. The pandemic-era DEA flexibility allowing controlled substance prescribing without an initial in-person exam has been extended through the end of 2025, and most expect it will be made permanent or further extended given the overwhelming evidence of safe, effective telehealth psychiatric care.

Here’s what that means practically:

• You can conduct initial evaluations via video
• You can initiate stimulant therapy (modafinil, amphetamines, methylphenidate) after a virtual assessment
• You can manage ongoing treatment with monthly telehealth follow-ups
• You must be licensed in the patient’s state
• You must comply with state-specific telehealth and controlled substance regulations

The reality is more nuanced than ‘yes’ or ‘no’ — it’s about understanding which medications you can prescribe, in which states, under what conditions. Let’s break it down.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Federal Telehealth Allowances: What the DEA Actually Says

During COVID-19, the DEA suspended the Ryan Haight Act requirement that controlled substances could only be prescribed after an in-person medical evaluation. That temporary allowance has been extended multiple times — most recently through December 31, 2025.

What this means for you:

You CAN currently:

• Prescribe Schedule II–V controlled substances via telehealth to new patients
• Continue prescribing to established patients you’ve never seen in person
• Use audio-visual telemedicine (video visits) to establish the provider-patient relationship
• E-prescribe controlled substances through DEA-compliant systems

You CANNOT:

• Prescribe via audio-only (phone calls) for new controlled substance prescriptions
• Prescribe to patients in states where you’re not licensed
• Ignore state-level restrictions that may be stricter than federal law

The extension through 2025 gives providers breathing room, but you should prepare for potential rule changes. The DEA has proposed new telemedicine registration pathways that would allow permanent telehealth prescribing with certain safeguards. Most psychiatrists and telehealth advocates expect some version of this to become permanent — the genie isn’t going back in the bottle after millions of successful virtual mental health visits.

State-by-State Reality Check: Where Psychiatrists Can Fully Manage Narcolepsy

While psychiatrists have broad federal authority, state telehealth laws can impose additional restrictions. Here’s the practical breakdown for key states:

Full Green Light States

California, New York, Illinois, Pennsylvania: Psychiatrists can prescribe all narcolepsy medications via telehealth without state-imposed limitations beyond federal requirements. These states have embraced telehealth parity and don’t distinguish between in-person and virtual prescribing for licensed physicians.

• New York requires all prescribers to check the I-STOP PDMP before every controlled substance prescription — this applies equally to telehealth
• California mandates CURES PDMP checks and e-prescribing for Schedule II drugs, but no additional telehealth barriers
• Illinois has full telehealth parity laws and no physician-specific controlled substance telehealth restrictions
• Pennsylvania allows telehealth prescribing; physicians face no special limitations (unlike NPs — more on that later)

States with Quirks You Must Know

Florida is the outlier that trips up providers. Florida law (as of SB 312 in 2022) prohibits prescribing Schedule II controlled substances via telehealth except for specific conditions:

• Psychiatric disorders (ADHD, treatment-resistant depression)
• Inpatient hospital care
• Hospice/palliative care
• Chronic pain management in certain settings

Here’s the problem: Narcolepsy is not classified as a psychiatric disorder. It’s a neurological condition (ICD-10 G47.4xx). Technically, a Florida-licensed psychiatrist treating narcolepsy via pure telehealth cannot prescribe Adderall or other Schedule II stimulants under state law.

Workarounds Florida psychiatrists use:

1. Prescribe modafinil or armodafinil (Schedule IV) instead — these are allowed via telehealth
2. Arrange at least one in-person visit with a local physician partner to satisfy the requirement
3. If the patient also has comorbid ADHD or another psychiatric indication, document that as the primary diagnosis

Texas doesn’t have an explicit telehealth ban for physicians, but requires the telemedicine visit meet the same standard of care as in-person (including video, proper documentation, and clinical appropriateness). Texas psychiatrists can prescribe narcolepsy medications via telehealth — but note that Texas is a restricted-practice state for NPs, which affects collaborative models.

What About Nurse Practitioners? The PMHNP vs MD Divide

This is where scope of practice gets complicated and state-specific. As a psychiatrist, you need to understand these differences if you’re:

• Considering hiring or collaborating with PMHNPs
• Competing with NP-run telehealth services
• Evaluating career opportunities in different states

States Where PMHNPs Can Manage Narcolepsy Independently

New York (after 3,600 hours of experience): Experienced PMHNPs practice fully independently without physician oversight. They can prescribe Schedule II–V medications, including stimulants for narcolepsy. Same PDMP requirements as MDs.

Illinois (after 4,000 hours + 250 CE hours): PMHNPs with Full Practice Authority can prescribe narcolepsy medications independently. Illinois does require a physician consultation relationship for Schedule II opioids and restrictions on long-term benzodiazepines, but stimulants are not restricted — a fully independent IL PMHNP can manage narcolepsy without MD involvement.

California (by 2026): The AB 890 pathway creates ‘104 NP’ status for experienced NPs (≥3 years in collaborative practice). By January 2026, California PMHNPs meeting criteria can practice and prescribe completely independently, including narcolepsy stimulants. Until then, they need standardized procedures with a physician.

States Where PMHNPs Are Severely Limited

Texas: This is where it gets restrictive. Texas NPs cannot prescribe Schedule II controlled substances except in very limited settings (hospital inpatient care or hospice). A Texas PMHNP working in outpatient telehealth cannot prescribe Adderall or Ritalin for narcolepsy — only the supervising physician can write those prescriptions.

Practically, this means Texas telehealth platforms treating narcolepsy need psychiatrists (MDs/DOs) on staff, or NPs must work collaboratively with physicians who handle all Schedule II prescribing.

Florida: PMHNPs require a collaborative agreement with a physician (they’re excluded from Florida’s autonomous practice pathway). Florida also limits NP Schedule II prescriptions to 7-day supplies unless the NP is a certified ‘psychiatric nurse’ treating a psychiatric condition. For narcolepsy (non-psychiatric), this means weekly prescription refills — administratively burdensome and impractical.

Pennsylvania: NPs must have a collaborative agreement and can prescribe Schedule II for maximum 30-day supply (versus 90 days for Schedule III–IV). A PA PMHNP can manage narcolepsy but with more frequent physician oversight and monthly prescription limitations.

Why This Matters for Psychiatrists

If you’re a psychiatrist considering telehealth platforms or independent practice:

Your competitive advantage: In restricted states like Texas and Florida, only psychiatrists can efficiently manage narcolepsy patients. You’re not competing with independent PMHNPs for this patient population — you’re the only option for stimulant management outside of neurology.

Collaboration opportunities: In states requiring NP supervision, telehealth companies need psychiatrists to provide oversight for PMHNPs treating narcolepsy. This can be a revenue stream (being paid for supervision/consultation) or a practice-building opportunity (capturing the more complex patients NPs must refer).

Practice location strategy: If you’re deciding where to get licensed for telehealth, states like New York, California, and Illinois offer the most competitive markets with both MD and NP providers, while Texas and Florida have artificially limited NP supply, creating higher demand for psychiatrists.

The Clinical Reality: What Narcolepsy Medication Management Actually Looks Like

Let’s talk about what you’re actually signing up for. Narcolepsy isn’t routine psychiatric prescribing — it has unique clinical and administrative demands.

Diagnosis Confirmation

Unlike ADHD where you can diagnose based on history and assessment, narcolepsy requires objective testing. Most psychiatrists will want documentation of:

• Polysomnography (PSG) ruling out sleep apnea
• Multiple Sleep Latency Test (MSLT) showing mean sleep latency <8 minutes with ≥2 sleep-onset REM periods (for narcolepsy type 1)
• Or low/absent CSF hypocretin-1 levels (rare, mostly research settings)

In telehealth practice, this means coordinating with:

• The patient’s sleep specialist who made the diagnosis
• Local sleep labs if new testing is needed
• Primary care for any baseline labs (especially if starting stimulants with cardiac history)

You’re not usually making the narcolepsy diagnosis yourself — you’re managing medications for a confirmed case. Think of it like managing diabetes: an endocrinologist diagnoses, but a PCP can adjust insulin.

Medication Options and Tiers

First-line for excessive daytime sleepiness:

• Modafinil (Provigil) 100–400 mg/day — Schedule IV, often requires prior auth
• Armodafinil (Nuvigil) 150–250 mg/day — Schedule IV, longer half-life
• Solriamfetol (Sunosi) 75–150 mg/day — Schedule IV, newer, very expensive
• Methylphenidate ER 18–72 mg/day — Schedule II
• Amphetamine salts (Adderall) 10–60 mg/day — Schedule II
• Dextroamphetamine — Schedule II

For cataplexy (narcolepsy type 1):

• Sodium oxybate (Xyrem/Xywav) — Schedule III, REMS program required
• Pitolisant (Wakix) — not controlled, expensive
• Tricyclic antidepressants (off-label) — older option
• SSRIs/SNRIs (off-label) — modest benefit

Most psychiatrists start with modafinil (if insurance covers it) due to lower abuse potential and Schedule IV status. If insurance denies or the patient doesn’t respond, amphetamine/methylphenidate are highly effective but come with Schedule II administrative burden.

The Prior Authorization Nightmare

Let’s be honest: insurance authorization for narcolepsy meds is a massive pain point. Nearly every narcolepsy medication requires prior auth because they’re expensive and considered specialty drugs.

What insurers typically require:

• Documented sleep study results (PSG + MSLT)
• ICD-10 diagnosis code (G47.411 for narcolepsy with cataplexy, G47.419 without)
• Trial and failure of ‘preferred’ medications (often modafinil first)
• Specialist letter confirming diagnosis
• Sometimes peer-to-peer review

This is non-billable time that eats into your schedule. If you’re working on a platform, check whether they have dedicated staff to handle prior auths. If you’re independent, build this time into your fee structure or consider cash-pay for quicker medication access.

One workaround: some patients choose to pay out-of-pocket for generic modafinil (~$50–$100/month) rather than deal with insurance paperwork. Amphetamines are usually cheaper through insurance (if approved) than out-of-pocket due to scrutiny and quantity limits.

Follow-Up Frequency and Reimbursement

Narcolepsy medication management is high-touch, short visits:

• Monthly visits during titration (first 3–6 months)
• Every 3 months once stable (aligns with quarterly med checks and prior auth renewals)
• 15–20 minute visits focused on: sleep attacks, Epworth Sleepiness Scale score, side effects (BP, weight, mood), medication adherence, dose adjustments

These visits code as 99213 or 99214 (established patient office visit, low to moderate complexity). Medicare allowable is roughly $90–$130 per visit depending on locality. Private insurance ranges $110–$180.

Annual revenue per narcolepsy patient (seeing every 3 months): ~$400–$600 in reimbursement. If you carry a panel of 30 stable narcolepsy patients, that’s $12,000–$18,000/year in predictable, straightforward visits.

The catch: Schedule II prescriptions cannot be refilled — you’re writing a new e-prescription monthly for stimulants. This is part of federal law, not a telehealth quirk. Build efficient e-prescribing workflows into your EHR.

The Stimulant Shortage Factor

Since mid-2022, the ongoing Adderall shortage has created real challenges. Patients call frantically when their pharmacy can’t fill prescriptions. The DEA and FDA have been under pressure to increase manufacturing quotas, but as of early 2024, shortages persist.

What this means for you:

• Be prepared to switch prescriptions quickly (methylphenidate instead of amphetamine, or vice versa)
• Have a list of alternative pharmacies or compounding options
• Educate patients about second-line therapies (modafinil, Sunosi)
• Document every medication switch and the reason (shortage vs. clinical decision)

Telehealth actually helps here — you can e-prescribe to any pharmacy nationwide (if licensed in that state), giving patients more flexibility than a paper script locked to one local pharmacy.

Compliance Must-Haves: What Could Get You in Trouble

Let’s talk about the regulatory landmines. Here’s what keeps psychiatrists out of trouble when prescribing controlled substances via telehealth:

1. PDMP Checks Every Time

Every state now has a Prescription Drug Monitoring Program, and most legally require you to check it before prescribing controlled substances. Some states (like New York) mandate checking before every controlled prescription. Others allow periodic checks (quarterly) for stable patients.

The PDMP shows:

• All controlled prescriptions the patient has filled in the past year
• Any doctor-shopping patterns (multiple prescribers)
• Any overlapping prescriptions that raise abuse concerns

Best practice: Check the PDMP at initial evaluation and then at least quarterly (or monthly for higher-risk patients). Document in your note that you reviewed it.

2. Use EPCS (Electronic Prescribing of Controlled Substances)

Paper prescriptions for Schedule II drugs are essentially obsolete. Most states now require e-prescribing for controlled substances, and telehealth makes paper scripts impossible anyway (you’re not handing the patient a script).

You need:

• DEA-compliant e-prescribing software
• Two-factor authentication
• Audit trails

Your EHR platform should handle this — if you’re on a telehealth platform, confirm they provide EPCS-enabled systems before joining.

3. Document Like It’s an In-Person Visit

The telehealth standard of care = in-person standard of care. Your documentation must be equally thorough:

• Chief complaint and symptom review
• Medication history (including all controlled substances)
• Side effect screening (BP, heart rate if on stimulants, mood changes)
• PDMP review documented
• Informed consent for controlled substances (at least initially)
• Any care coordination with sleep specialist or PCP

Many state medical boards have guidance documents on telehealth documentation. When in doubt, over-document.

4. State Licensure in the Patient’s Location

You must be licensed in the state where the patient is physically located at the time of the visit. Interstate compacts (like PSYPACT for psychologists) don’t cover physician prescribing.

If you want to practice in multiple states via telehealth:

• Apply for licensure in each state (or use the Interstate Medical Licensure Compact for easier multi-state licensing if your home state participates)
• Track where each patient is located (platforms usually verify this at login)
• Don’t prescribe if the patient crosses state lines mid-treatment without you having that license

5. Know Your Malpractice Coverage

Check that your malpractice insurance covers:

• Telehealth practice
• Controlled substance prescribing
• Multi-state practice (if applicable)

Most carriers now cover telehealth, but confirm. The risk of a DEA investigation or malpractice claim is low if you’re practicing evidence-based care and following PDMP/documentation rules, but you want to be protected.

Why Narcolepsy Patients Are Actually Ideal for Telehealth (Despite the Regulatory Hassle)

Let’s end with the upside. Once you navigate the regulatory complexity, narcolepsy patients are excellent telehealth candidates:

They can’t always travel safely: Patients with narcolepsy have unpredictable sleep attacks. Asking them to drive 60 miles to a psychiatrist’s office is both impractical and dangerous. Telehealth removes that barrier entirely.

They’re medication-focused: Unlike anxiety or depression where psychotherapy is often the core treatment, narcolepsy management is primarily pharmacological. These 15-minute med checks are perfectly suited for video visits.

They’re long-term, stable patients: Once you find the right medication and dose, narcolepsy patients stay on treatment for years or decades. They become a reliable, low-drama part of your panel — quarterly check-ins, rare emergencies, predictable billing.

They’re underserved: There’s a massive shortage of providers treating narcolepsy. Most sleep specialists focus on sleep apnea (the bread-and-butter of sleep medicine). Psychiatrists willing to manage narcolepsy meds fill a real gap, especially in rural areas.

They’re often young and employed: Many narcolepsy patients are in their 20s–40s, working, and motivated to stay on treatment. They tend to be reliable with appointments and payments (whether insurance or cash-pay). Lower no-show rates than some psychiatric populations.

How Platforms Like Klarity Health Make This Actually Workable

Here’s the economic reality: building an independent telehealth practice to treat narcolepsy means:

• Multi-state licensing fees ($500–$2,000 per state)
• Malpractice insurance ($5,000–$15,000/year)
• EHR with EPCS capability ($200–$500/month)
• Marketing to find narcolepsy patients (SEO, Google Ads, directory listings — often $3,000–$5,000/month in spend before seeing ROI)
• Prior authorization staff or your own unpaid time
• No-show risk from cold leads

Most solo psychiatrists don’t have the patience or capital for this, especially when you’re already earning $200–$300/hour seeing established patients in traditional practice.

Platforms flip the economics: Instead of paying thousands upfront to maybe acquire patients, you pay only when a qualified patient books with you.

Here’s why that matters for narcolepsy specifically:

Pre-qualified patients: The platform matches patients who already have a narcolepsy diagnosis (or strong clinical suspicion) to your specialty and availability. You’re not fishing for patients — they’re already seeking exactly what you offer.

No marketing spend: Instead of gambling $5,000/month on Google Ads competing with every psychiatrist in your state, you pay a standard listing fee per new patient lead. Only when they book. That’s guaranteed ROI vs. hoping your SEO works in 12 months.

Built-in compliance infrastructure: The platform provides EPCS-enabled e-prescribing, PDMP integration, telehealth-compliant documentation templates, and often prior authorization support. You’re not cobbling together five different vendors.

Both insurance and cash-pay flow: Narcolepsy patients come through insurance panels (where the platform handles billing and credentialing) and cash-pay options (for patients who want faster access or have high-deductible plans). You control your schedule and rates.

State-by-state licensure support: Many platforms help with multi-state licensing paperwork or connect you to services that expedite the process (like the Interstate Medical Licensure Compact).

The value proposition for psychiatrists is simple: focus on clinical care, not business administration. You control when you see patients, which states you’re licensed in, and whether you take insurance. The platform handles patient acquisition, compliance systems, and administrative overhead.

For narcolepsy specifically, this removes the biggest barrier: finding the small patient population who need this specialized care. Narcolepsy affects ~1 in 2,000 people — trying to attract them through your own marketing is a needle-in-haystack problem. A platform with national reach and targeted patient outreach solves that instantly.

The Bottom Line for Psychiatrists

Yes, psychiatrists can prescribe narcolepsy medications via telehealth in most states — and it’s often the most practical way to serve this underserved patient population.

You need to:

• Understand federal DEA allowances (currently extended through 2025)
• Know your state’s specific rules (especially Florida’s Schedule II telehealth ban)
• Recognize where you have competitive advantages over NPs (Texas, Florida, Pennsylvania)
• Build efficient workflows for PDMP checks, e-prescribing, and prior auths
• Prepare for monthly follow-ups during titration, quarterly for stable patients

The regulatory complexity is real, but it’s manageable with the right systems and support. And the patient need is enormous — an estimated 160,000 Americans have narcolepsy, and most struggle to find knowledgeable providers.

If you’re considering telehealth practice, narcolepsy medication management offers:

• Stable, long-term patient relationships
• Straightforward, billable med check visits
• Less competition than general psychiatry (ADHD, anxiety, depression)
• Genuine impact on patients’ quality of life and safety

The platform model makes the most economic sense: avoid the upfront costs and uncertainty of DIY marketing, skip the administrative burden of building your own telehealth infrastructure, and start seeing patients who actually need your expertise.

Ready to explore treating narcolepsy patients via telehealth? Join Klarity Health’s provider network and get matched with pre-qualified patients in states where you’re licensed — without spending a dollar on marketing until you see your first patient.

FAQ: Psychiatrists Prescribing Narcolepsy Medication via Telehealth

Can a psychiatrist diagnose narcolepsy via telehealth, or only manage medications?

Most psychiatrists manage medications for narcolepsy patients already diagnosed by a sleep specialist. Narcolepsy diagnosis requires objective sleep testing (polysomnography and Multiple Sleep Latency Test) that must be done in a sleep lab. While a psychiatrist could technically diagnose narcolepsy based on clinical history and refer for confirmatory testing, in practice most take over care after diagnosis is established. You can absolutely conduct initial evaluations via telehealth to review sleep study results and initiate treatment.

What’s the difference between prescribing for narcolepsy vs. ADHD via telehealth?

Both conditions often use the same medications (stimulants like Adderall or Ritalin), but narcolepsy requires documented sleep study results for diagnosis and insurance approval. ADHD can be diagnosed clinically via telehealth assessment. From a legal/regulatory standpoint, there’s no difference in prescribing authority — both are legitimate uses of Schedule II stimulants. The main practical difference is prior authorization burden (narcolepsy meds almost always require PA; ADHD meds increasingly do but not universally).

If the DEA waiver expires in 2025, will I need an in-person exam for narcolepsy patients?

Possibly, but advocacy groups and medical associations are pushing for permanent telehealth prescribing authority. If the waiver expires without replacement rules, psychiatrists would technically need an in-person exam before prescribing Schedule II drugs to new patients. However, established patients (those you’ve already started on medication) would likely be grandfathered. The DEA has proposed new telemedicine registration options that would allow remote prescribing with additional safeguards — most expect some version of this to become permanent.

Can I prescribe sodium oxybate (Xyrem/Xywav) via telehealth for narcolepsy with cataplexy?

Yes, but you must be enrolled in the Xyrem/Xywav REMS (Risk Evaluation and Mitigation Strategy) program. This requires completing a prescriber enrollment form and following specific dispensing protocols — there’s only one central pharmacy that distributes these medications. The REMS program doesn’t prohibit telehealth; you can manage patients remotely as long as you maintain proper documentation and follow-up schedules (usually monthly initially, then every 3 months). The pharmacy handles patient education on safe use.

Do I need malpractice insurance that specifically covers telehealth and controlled substance prescribing?

Check with your malpractice carrier, but most now include telehealth within standard coverage (it’s no longer considered a special risk). However, if you’re practicing in multiple states via telehealth, you may need a multi-state policy or specific endorsements. For controlled substance prescribing, as long as you’re following evidence-based guidelines, using PDMP databases, and documenting appropriately, there’s no additional coverage usually needed — this is considered standard psychiatric practice.

What happens if a narcolepsy patient moves to a different state mid-treatment?

You cannot continue prescribing unless you’re licensed in their new state. If a patient relocates, they need to either: (1) transfer care to a provider in the new state, (2) wait for you to obtain licensure there if you’re willing, or (3) return to your state for in-person visits if they live close to the border. Most telehealth platforms track patient location at each visit and will flag if someone logs in from a different state. This is one advantage of being on a multi-state platform — you may already have the license you need, or the platform can fast-track it.

How do I handle the Adderall shortage when treating narcolepsy patients via telehealth?

Have backup medication options ready: if amphetamine salts are unavailable, switch to methylphenidate ER (Concerta), dexmethylphenidate (Focalin), or dextroamphetamine. You can also consider non-stimulant alternatives like modafinil if appropriate (though some patients respond better to traditional stimulants). E-prescribing helps because you can quickly send a new prescription to an alternative pharmacy. Document in your notes that the medication change was due to shortage, not clinical failure — this matters for insurance and continuity of care.

Can I bill the same E/M codes for telehealth narcolepsy visits as in-person?

Yes. Telehealth parity laws in most states require insurers to reimburse telehealth visits at the same rate as in-person for the same service. You’ll use the same CPT codes (99213, 99214 for established patient visits) and add a telehealth modifier or place of service code as required by the payer. Medicare and most commercial plans now pay telehealth psychiatry at parity. Some states (like Illinois, California, New York) have explicit parity laws; others allow it by policy. Just ensure you’re using video (audio-visual), not phone-only, as most payers require video for controlled substance prescribing visits.

Sources & Citations

1. Axios (Nov 18, 2024) – ‘COVID-era telehealth prescribing extended again for Adderall, other controlled substances’ – Reports DEA/HHS extension of telehealth controlled substance allowances through December 2025. www.axios.com

2. National Law Review (Apr 7, 2022) – ‘New Florida Law Allows Telemedicine Prescribing of Certain Controlled Substances’ – Legal analysis of Florida SB 312 telehealth prescribing restrictions, specifically Schedule II limitations and exceptions for psychiatric treatment. natlawreview.com

3. California Board of Registered Nursing (Updated 2024) – ‘AB 890 – Nurse Practitioner Practice’ – Official guidance on California’s NP independence pathway, 103/104 NP categories, and timeline for autonomous practice by 2026. www.rn.ca.gov

4. Illinois General Assembly – ‘Nurse Practice Act, 225 ILCS 65/’ – Full text of Illinois NP Full Practice Authority law including prescribing requirements, consultation rules for Schedule II narcotics, and 4000-hour experience threshold. www.ilga.gov

5. Florida Senate (2021 Statutes) – ‘Chapter 464 – Nursing’ – Florida Nurse Practice Act detailing APRN prescribing authority, 7-day Schedule II supply limit, and psychiatric nurse exemption. www.flsenate.gov

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20and,person%20doctor%27s%20visit%20for%20the
• https://natlawreview.com/article/new-florida-law-allows-telemedicine-prescribing-controlled-substances#:~:text=controlled%20substances%20via%20telemedicine%2C%20with,more%20on
• https://www.ilga.gov/legislation/ILCS/details?ActID=1312&ActName=Nurse+Practice+Act.&ChapAct=225+ILCS+65%2F&Chapter=&ChapterID=24&MajorTopic=&Print=True&SeqEnd=17850000&SeqStart=16500000#:~:text=,drugs%2C%20such%20as
• https://www.ilga.gov/legislation/ILCS/details?ActID=1312&ActName=Nurse+Practice+Act.&ChapAct=225+ILCS+65%2F&Chapter=&ChapterID=24&MajorTopic=&Print=True&SeqEnd=17850000&SeqStart=16500000#:~:text=,require%20a%20physician%20name%3B
• https://www.rivkinrounds.com/2022/04/new-law-allows-experienced-nps-to-practice-independently-in-ny/#:~:text=New%20York%E2%80%99s%202023%20state%20budget%2C,practice%20without%20a%20collaborative%20relationship
• https://www.rn.ca.gov/practice/ab890.shtml#:~:text=%2A%20103%20NP%20,focus%20of%20their%20National%20Certification
• https://www.rn.ca.gov/practice/ab890.shtml#:~:text=Please%20note%2C%20the%20law%20requires,certify%20104%20NPs%20until%202026
• https://www.tmb.state.tx.us/274-who-can-prescribe-schedule-ii-drugs-under-physician-delegation#:~:text=1.%20in%20a%20hospital%20facility,has%20elected%20to%20receive%20hospice
• https://www.flsenate.gov/Laws/Statutes/2021/Chapter464/All#:~:text=match%20at%20L1566%20limit%20the,455
• https://www.pacodeandbulletin.gov/Display/pacode?file=%2Fsecure%2Fpacode%2Fdata%2F049%2Fchapter21%2Fs21.284.html#:~:text=,may%20not%20delegate%20prescriptive%20authority